Choriogonadotropin alfa
Current shortage
The TGA records this medicine as being in shortage now. A shortage often affects some brands, strengths or pack sizes and not others, so a supply of the medicine may still be available. Your pharmacist can tell you what is in stock and what alternatives exist.
The TGA has assessed this shortage as critical impact. That is a judgement about how hard the medicine is to substitute in clinical care, not a prediction about any one person. If you take this medicine, speak to your pharmacist or doctor about what is available. Do not stop or change how you take it on your own.
1 product record on the Australian Register of Therapeutic Goods, listed in full below. The TGA last updated this information on 28 June 2024. Not medical advice.
The TGA does not publish a reason for a shortage, so Voxsanity cannot show one. Nothing on this page is an explanation of why supply is affected — that information is not in the source and is not inferred here.
This is national information. The TGA records shortages for Australia as a whole. There is no state, territory or pharmacy-level stock information in this data, and Voxsanity cannot tell you whether a particular pharmacy has a medicine in stock. Your pharmacist can.
Products affected
OVIDREL choriogonadotropin alfa (rch) 250 microgram/ 0.5mL solution for injection pre-filled pen
Injection, solution · ARTG 170446
Read the TGA's own shortage record for this product
- Status
- Current shortage The TGA records this medicine as being in shortage now. A shortage often affects some brands, strengths or pack sizes and not others, so a supply of the medicine may still be available. Your pharmacist can tell you what is in stock and what alternatives exist.
- Supply
- Limited Availability The supplier reports limited stock.
- TGA impact rating
- Critical impact The TGA has assessed this shortage as critical impact. That is a judgement about how hard the medicine is to substitute in clinical care, not a prediction about any one person. If you take this medicine, speak to your pharmacist or doctor about what is available. Do not stop or change how you take it on your own.
- Reported from
- 1 July 2024 The TGA's dates span 7 years, 6 months.
- Expected to be resolved
- 31 December 2031 This is the date the supplier has given the TGA. It can move.
- TGA last updated
- 28 June 2024
What the TGA says is being done
The sponsor is closely controlling the supply. An overseas-registered product has been approved for supply under section 19A. The approval holder, Merck Healthcare Pty Ltd, can be contacted for details on supply on 1800 633 463.
Quoted from the TGA's own record for this product. Voxsanity has not edited, summarised or interpreted it.
Terms like ARTG, TGA and PBS are explained in the glossary.
Where this comes from
Source: Medicine Shortage Reports Database, Therapeutic Goods Administration (TGA), © Commonwealth of Australia, reproduced with permission. The TGA does not endorse Voxsanity, and nothing here is presented as a TGA view. Shortage information is free for everyone on this site, with no account and no subscription.
Every product listed above links to the TGA's own shortage record for that product. The TGA's register is organised by product rather than by medicine, so there is no single TGA page covering Choriogonadotropin alfa as a whole; to see them together, open the TGA Medicine Shortage Reports Database and type Choriogonadotropin alfa into its filter box. General information about medicine shortages is on the TGA's medicine shortages page.
Voxsanity last read the register on 16 October 2026.
Not medical advice. Voxsanity republishes public government health data in plain English. Speak to your pharmacist or doctor about your own medicines. Do not stop or change how you take a medicine because of anything on this page.